Current schizophrenia drugs: efficacy and side effects
- 24 May 2006
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 7 (8), 1005-1016
- https://doi.org/10.1517/14656566.7.8.1005
Abstract
Over the course of the past decade, the acceptance of several second-generation antipsychotics (SGAs) as effective medication for the treatment of schizophrenia has led to some changes. SGAs have a lower risk of inducing extrapyramidal side effects and tardive dyskinesia compared with first-generation antipsychotics, and have been said to be more successful in long-term treatment and tolerability. They also significantly improve the quality of life of schizophrenic patients. However, during treatment with SGAs other adverse effects can occur, such as weight gain, metabolic changes, sexual dysfunction and QTc-prolongation, significantly affecting the patient's physical health. Consequently, these side effects might be the reason that a high proportion of patients discontinue treatment with SGAs. Thus, from the authors' view, optimising individualised treatment implies increasing the efficacy of current schizophrenia drugs. This can be achieved by finding clinical or pharmacogenetic predictors for the most appropriate drug or drug combination, and by improving side-effect management in combination with non-pharmacological interventions in order to increase patients' quality of life and treatment compliance, possibly resulting in a better long-term outcome.Keywords
This publication has 90 references indexed in Scilit:
- Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?Schizophrenia Bulletin, 2005
- Low Gene Expression Conferred by Association of an Allele of the 5-HT2CReceptor Gene With Antipsychotic-Induced Weight GainAmerican Journal of Psychiatry, 2005
- Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapineJournal of Clinical Pharmacy & Therapeutics, 2005
- Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter ExpressionPharmacopsychiatry, 2004
- Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophreniaSchizophrenia Research, 2004
- Current Issues in SchizophreniaCNS Drugs, 2004
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004
- Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapyPsychological Medicine, 2003
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- Risk Facotrs for Posttraumatic Stress DisorderBritish Journal of Psychology, 2000